<DOC>
	<DOCNO>NCT02240108</DOCNO>
	<brief_summary>The primary objective determine efficacy rifaximin DR tablet vs. placebo induction clinical remission endoscopic response follow 16 week treatment subject present active moderate Crohn 's disease . A key secondary objective evaluate clinical endoscopic remission follow additional 36 week treatment .</brief_summary>
	<brief_title>One Year Study Rifaximin Delayed Release ( DR ) Crohn 's Disease</brief_title>
	<detailed_description>RECD3126 double-blind , placebo-controlled , parallel-group , multicenter , multiregional , 52-week study ass efficacy safety rifaximin DR tablets induction clinical remission endoscopic response 16 week follow clinical endoscopic remission 52 week continuous therapy subject active moderate Crohn 's disease . Subjects randomized 1:1 allocation rifaximin placebo begin treatment period maintain treatment assignment throughout duration study . Ileocolonoscopy perform subject baseline , Weeks 16 17 ( end Induction Phase ) , follow completion 36-week Long Term Treatment Phase ( Week 52 ) .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>Major Moderate , nonfistulizing Crohn 's disease ileum and/or prior randomization ; SESCD score â‰¥7 ( confirm centralize endoscopy read ) . During Screening Period , subject need certain average daily score abdominal pain average number liquid/very soft stool . Major Pregnant lactate female . Females childbearing ( reproductive ) potential must negative serum pregnancy test screen agree use highly effective method ( ) contraception throughout participation study . Diagnosis ulcerative indeterminate colitis . Diagnosis Celiac Disease . Bowel surgery within 12 week prior screen and/or surgery plan deem likely Crohn 's disease study period . Presence ileostomy colostomy . Known fixed symptomatic stenosis/stricture small large bowel . Had one segmental colonic resection . Had 3 small bowel resection symptom associate short bowel syndrome . Current evidence peritonitis . History evidence colonic mucosal dysplasia . History evidence adenomatous colonic polyp remove . Unwilling tapered corticosteroid Week 8 subject know Investigator steroid dependent . Has use biologic within 12 week randomization . Used cyclosporine , tacrolimus , sirolimus , mycophenolate mofetil , similar drug within 8 week prior randomization . Had rectal administration 5aminosalicylic acid ( 5ASA ) corticosteroid enemas/foams/ suppository within 2 week prior screen visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Crohn 's Disease</keyword>
	<keyword>Rifaximin</keyword>
	<keyword>Clinical remission endoscopic response</keyword>
	<keyword>Inflammatory Bowel Disease</keyword>
</DOC>